Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee J Helman

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|September 11, 2008
Progress in the curative treatment of childhood hematologic malignanciesAlan S Wayne, Gregory H Reaman, Lee J Helman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2012
Targeting cancer metabolismBeverly A Teicher, W Marston Linehan, Lee J Helman
Cancer Research|March 23, 2005
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcomaXiaolin Wan, Arnulfo Mendoza, Chand Khanna, et al.
The New England Journal of Medicine|July 3, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumorsSosipatros A Boikos, Lee J Helman, Constantine A Stratakis, et al.
Oncogenesis|February 28, 2019
Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growthSameer H Issaq, Arnulfo Mendoza, Stephen D Fox, et al.
Neoplasia (New York, N.Y.)|May 1, 2015
IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in RhabdomyosarcomaXiaolin Wan, Choh Yeung, Christine Heske, et al.
Neoplasia (New York, N.Y.)|June 23, 2006
CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signalingXiaolin Wan, Na Shen, Arnulfo Mendoza, et al.
The Oncologist|January 8, 2009
The role of IGF-1R in pediatric malignanciesSu Young Kim, Jeffrey A Toretsky, Daniel Scher, et al.
Pediatric Blood & Cancer|October 16, 2020
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studiesKatherine K Slemmons, Sanjit Mukherjee, Paul Meltzer, et al.
Clinical & Experimental Metastasis|October 10, 2006
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathwayKartik Krishnan, Ben Bruce, Stephen Hewitt, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|September 11, 2008
Progress in the curative treatment of childhood hematologic malignanciesAlan S Wayne, Gregory H Reaman, Lee J Helman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2012
Targeting cancer metabolismBeverly A Teicher, W Marston Linehan, Lee J Helman
Cancer Research|March 23, 2005
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcomaXiaolin Wan, Arnulfo Mendoza, Chand Khanna, et al.
The New England Journal of Medicine|July 3, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumorsSosipatros A Boikos, Lee J Helman, Constantine A Stratakis, et al.
Oncogenesis|February 28, 2019
Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growthSameer H Issaq, Arnulfo Mendoza, Stephen D Fox, et al.
Neoplasia (New York, N.Y.)|May 1, 2015
IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in RhabdomyosarcomaXiaolin Wan, Choh Yeung, Christine Heske, et al.
Neoplasia (New York, N.Y.)|June 23, 2006
CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signalingXiaolin Wan, Na Shen, Arnulfo Mendoza, et al.
The Oncologist|January 8, 2009
The role of IGF-1R in pediatric malignanciesSu Young Kim, Jeffrey A Toretsky, Daniel Scher, et al.
Pediatric Blood & Cancer|October 16, 2020
LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studiesKatherine K Slemmons, Sanjit Mukherjee, Paul Meltzer, et al.
Clinical & Experimental Metastasis|October 10, 2006
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathwayKartik Krishnan, Ben Bruce, Stephen Hewitt, et al.
Pageof 10